NASDAQ:GRTS • US39868T1051
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GRITSTONE BIO INC (GRTS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-10-02 | Jones Trading | Downgrade | Buy -> Hold |
| 2024-10-02 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2024-10-01 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-10-01 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-05 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-08-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-14 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-05-24 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-02 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-03-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-28 | JMP Securities | Initiate | Market Outperform |
| 2023-09-28 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-28 | B. Riley Securities | Initiate | Buy |
| 2023-03-14 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-07 | HC Wainwright & Co. | Maintains | Buy |
| 2022-10-31 | Piper Sandler | Initiate | Overweight |
| 2022-08-22 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2022-05-09 | HC Wainwright & Co. | Maintains | Buy |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 48.21M 1,093.32% | 19.95M -58.62% | 16.344M -18.08% | 2.907M -82.21% | -100.00% | 12.227M | 59.962M 390.41% | 185.48M 209.33% | 519.42M 180.04% | 878.05M 69.04% | |
| EBITDA YoY % growth | -68.86M 30.71% | -113.87M -65.36% | -132.03M -15.95% | -132.214M -0.14% | -156.844M -18.63% | -161.779M -3.15% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -75.21M 29.06% | -120.43M -60.12% | -139.621M -15.94% | -132.98M 4.76% | -147.851M -11.18% | -180.203M -21.88% | -211.121M -17.16% | -144.998M 31.32% | 146.24M 200.86% | 467.61M 219.76% | |
| Operating Margin | -156.00% | -603.66% | -854.26% | -4,574.49% | N/A | -1,473.82% | -352.09% | -78.17% | 28.15% | 53.26% | |
| EPS YoY % growth | -0.96 65.47% | -1.33 -38.54% | -1.20 9.77% | -0.97 19.29% | -1.00 -3.11% | -1.15 -14.74% | -0.43 62.61% | 0.18 142.86% | 0.99 438.89% | 1.66 68.04% |
All data in USD
| Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.19 42.51% | -0.23 12.85% | -0.18 46.00% | -0.17 -8.38% | -0.17 8.60% | -0.17 23.47% |
| Revenue Q2Q % growth | -100.00% | 5.526M -46.78% | 1.734M -0.46% | 1.734M 88.27% | 1.836M | 1.836M -66.78% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -40.036M -3.72% | -34.681M -13.82% | -29.58M 25.68% | -30.09M -9.07% | -30.09M 24.84% | -30.6M 11.77% |
All data in USD
6 analysts have analysed GRTS and the average price target is 0.77 USD. This implies a price increase of 2275.78% is expected in the next year compared to the current price of 0.0322.
GRITSTONE BIO INC (GRTS) will report earnings on 2024-11-07, after the market close.
The consensus EPS estimate for the next earnings of GRITSTONE BIO INC (GRTS) is -0.19 USD and the consensus revenue estimate is 0 USD.
The consensus rating for GRITSTONE BIO INC (GRTS) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.